Vanda Pharmaceuticals (VNDA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vanda Pharmaceuticals

NasdaqGM•Healthcare•Biotechnology

$5.33-0.10(-0.02%)Pre-market

Market Cap

$307.76M

P/S

1.4x

P/B

1.4x

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (2/25).

Profitability2/25

Growth13/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 96.8x5y range 21.1x – 96.8x

Currently above its 10-quarter median.

P/S · 1.4x5y range 1.2x – 3.5x

Currently near its 20-quarter median.

P/B · 1.4x5y range 0.4x – 1.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $307.76M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $215.72M
Q. Revenue: $50.53M
TTM EBITDA: $-177.00M
TTM Op. Income: $-185.67M
Q. Op. Income: $-63.81M
TTM Net Income: $-274.85M
Q. Net Income: $-62.51M
EPS: $-1.04
Shares Out.: $60.23M

$215.72M in TTM revenue grew 6.0% YoY, reaching $50.53M last quarter. TTM EBITDA of $-177.00M and TTM operating income of $-185.67M show growth is flowing through to the bottom line. However, net income is negative at $274.85M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 6% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -121.3%
Op. Margin: -126.3%
Net Margin: -123.7%

Op. margin of -126.3% is down 53.1% YoY — costs are rising relative to revenue. Net margin at -123.7% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.4x
P/B Ratio: 1.4x

P/S of 1.4x and P/B of 1.4x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $412.47M
Cash: $55.88M
Long-Term Debt: N/A
Book Value: $220.19M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-31.07M
TTM Free Cash Flow: $-143.00M
FCF Margin: -66.3%
FCF / Net Income: 0.5

TTM FCF of $-143.00M on $-31.07M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 6 consecutive quarters — a weakening trend.